合肥汇通控股股份有限公司关于2025年股票期权激励计划首次授予结果的公告

Core Viewpoint - Hefei Huitong Holdings Co., Ltd. has approved the initial grant of stock options under the 2025 Stock Option Incentive Plan, with a total of 2.38 million options granted to 79 eligible participants at an exercise price of 28.04 yuan per option [1][3][4]. Group 1: Stock Option Grant Details - The initial authorization date for the stock options is December 31, 2025 [2]. - A total of 2.38 million stock options have been granted [3]. - The number of participants receiving the stock options is 79, including directors, senior management, and key personnel [3]. - The exercise price for the stock options is set at 28.04 yuan per option [4]. - The stock options are sourced from the company's A-share ordinary stock issued to the incentive participants [5]. Group 2: Distribution and Registration - The stock options have been distributed among the participants, with no individual participant receiving more than 1% of the company's total share capital at the time of the plan announcement [6]. - The total number of stock options granted does not exceed 10% of the company's total share capital at the time of the plan announcement [6]. - The registration for the initial grant of stock options was completed on January 27, 2026 [7]. Group 3: Plan Duration and Conditions - The effective period of the incentive plan lasts until all granted stock options are exercised or canceled, with a maximum duration of 70 months [8]. - The plan includes specific waiting periods and exercise arrangements for the stock options [8]. Group 4: Financial Impact - The company will adjust the expected number of exercisable stock options based on the latest information on eligible participants and performance indicators, in accordance with accounting standards [9]. - The estimated accounting costs related to the stock options will be influenced by various factors, including the exercise price and the number of options granted [9]. - The potential positive impact of the incentive plan on company performance is expected to outweigh the costs associated with the stock options [12].